Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model

Cancer Immunology, Immunotherapy

Volumn 56, Issue 4, 2007, Pages 459-468

  Lutterbuese, Petra ^a   Brischwein, Klaus ^a   Hofmeister, Robert ^a   Crommer, Sandrine ^a   Lorenczewski, Grit ^a   Petersen, Laetitia ^a   Lippold, Sandra ^a   Da Silva, Antonio ^a   Locher, Mathias ^a   Baeuerle, Patrick A ^a   Schlereth, Bernd ^a  

^a MICROMET AG   (Germany)

Author keywords

ADCC; Adecatumumab; EpCAM; Fc domain; Monoclonal antibody; Syngeneic mouse model

Indexed keywords

ADECATUMUMAB; FC RECEPTOR; MONOCLONAL ANTIBODY; MU ADECATUMUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; FC GAMMA RECEPTOR IIA; FCGR1A PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MT201 ANTIBODY, HUMAN; TACSTD1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG RECEPTOR BINDING; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; LOADING DRUG DOSE; LUNG METASTASIS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA HALF LIFE; PRIORITY JOURNAL; SPECIES DIFFERENCE; SPLEEN CELL; TREATMENT OUTCOME; ANIMAL; CHO CELL; COMPARATIVE STUDY; CRICETULUS; DISEASE MODEL; HAMSTER; IMMUNOLOGY; ISOGRAFT; LUNG TUMOR; METASTASIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; RECEPTORS, IGG; SPECIES SPECIFICITY; TRANSPLANTATION, ISOGENEIC;

EID: 33846837662     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0218-7     Document Type: Article

References (19)

1. Blumenthal RD, Osorio L, Hayes MK, Horak ID, Hansen HJ, Goldenberg DM (2005) Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother 54:315-327
2. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
3. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446
4. Dall'Ozzo S, Andres C, Bardos P, Watier H, Thibault G (2003) Rapid single-step FCGR3A genotyping based on SYBR Green I Xuorescence in real-time multiplex allele-specific PCR. J Immunol Methods 277:185-192
5. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900-3908
6. Golay J, Gramigna R, Facchinetti V, Capello D, Gaidano G, Introna M (2002) Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 119:923-929
7. Goldberg RM (2005) Cetuximab. Nat Rev Drug Discov (Suppl.): S10-S11
8. Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne-Bruns D, Kremer B (1997) Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J Surg Oncol 64:222-230
9. Maloney DG, Smith B, Rose A (2002) Rituximab: mechanism of action and resistance. Semin Oncol 29:2-9
10. Mellstedt H (2003) Monoclonal antibodies in human cancer. Drugs Today (Barc) 39(Suppl. C):1-16
11. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmuller G, Baeuerle PA, Dreier T (2002) In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100:101-110
12. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K (2004) Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64:2127-2133
13. Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ (2005) Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 92:342-349
14. Preithner S, Elm S, Lippold S, Locher M, Wolf A, Silva AJ, Baeuerle PA, Prang NS (2006) High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 43(8):1183-1193
15. Raum T, Gruber R, Riethmuller G, Kufer P (2001) Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens. Cancer Immunol Immunother 50:141-150
16. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60-70
17. Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM (1996) Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 19:184-191
18. Takai T (2002) Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2:580-592
19. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947